MEMaya V. Epifanova

Maya V. Epifanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maya V. Epifanova has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunophenotypic Features of CD68 and CD163 Distribution in Oral Squamous Cell Carcinoma of Tongue and Lip

    by Grigory Demyashkin, Andrey Kostin, Maya Epifanova, Alexandr Epifanov, Ekaterina Blinova, Anton Kasianov, Vladimir Shchekin, Dibakhan Tsomartova, Matvey Vadyukhin, Petr Shegai, et al.

    Background and Objectives: Oral squamous cell carcinoma (OSCC) belongs to a broad group of malignant neoplasms of the head and neck. It is known that components of the tumor microenvironment (TME) influence tumor progression. Similar patterns are being actively investigated in OSCC. In particular, a high density of CD68+ macrophages is associated with longer survival, whereas an abundance of M2 macrophages (CD163+) correlates with metastasis and an unfavorable prognosis. The present study compares the density and spatial distribution of CD68+ and CD163+ macrophages between intratumoral and peritumoral compartments in OSCC of the tongue and lip. Materials and Methods: Data from 112 patients with a verified OSCC diagnosis were included in this study. For the comparative morphological analysis, two core groups were formed: (a) Group I (n = 84), patients with Squamous Cell Carcinoma (pT1) of the tongue; (b) Group II (n = 28), patients with Squamous Cell Carcinoma (pT1) of the lip. Immunohistochemistry was performed according to standard protocols. Results: Tongue OSCC was characterized by the predominant accumulation of both CD68+ and CD163+ macrophages in the peritumoral stroma compared with the intratumoral zones (34.2 ± 8.1 vs. 48.1 ± 6.4 cells/mm2). In contrast, in lip OSCC, a higher density of CD68+ macrophages was observed in the intratumoral compartment, whereas the number of CD163+ macrophages remained considerably lower in both the intratumoral (51.1 ± 4.3 vs. 9.4 ± 2.1 cells/mm2) and peritumoral stroma of the tumor. Conclusions: These findings demonstrate that tongue and lip OSCC harbor distinct patterns of macrophage distribution and polarization, underscoring the role of the immune microenvironment in the biological heterogeneity of OSCC and warranting further investigation into macrophage subtype-specific prognostic markers.

  • Study of the combined use of the drug bovhyaluronidase azoximer and extracorporeal shock wave therapy in patients with chronic prostatitis

    by M. V. Epifanova, А. А. Kostin, E. V. Slavkina, S. A. Artemenko, А. А. Epifanov

    Introduction: the problem of treating chronic prostatitis (CP), due to its negative impact on quality of life, requires the search for effective methods of treatment. The study objective: to evaluate the efficacy and safety of the combined use of extracorporeal shock wave therapy (ESWT) and the drug bovhyaluronidase azoximer in the treatment of patients with CP. Materials and methods: the research included 70 men (mean age 44.8 ± 7.3 years) with CP, fibrotic changes and/ or calcinates in the prostate according to transrectal ultrasound (TRUS). According to the NIDDK/NIH classification, рatients with category II CP were divided into group 1 ( n = 20) — ESWT, 3-As-therapy, while patients with category IIIA and IIIB CP were randomized into group 2 ( n = 20) — ESWT monotherapy, and group 3 ( n = 30) — ESWT, the drug bovhyaluronidase azoximer. All participants underwent ESWT sessions targeting the perineum twice a week for 6 weeks. Assessments were conducted at baseline, weeks 7, 10, and 18, and included NIH-CPSI, IPSS, IIEF-5, VAS, uroflowmetry, TRUS, prostate secretion microscopy/sperm analysis, culture of prostate secretion/sperm, total PSA levels for men over 50 years. Results: by week 18, the intragroup results showed improvement in laboratory parameters, erectile function, relief from pain and dysuria, reduction in prostate volume, calcinates and fibrosis size ( p < 0.05). Analysis of variance between groups showed significant differences in NIH-CPSI, IPSS, VAS, Qmax, Qave, prostate volume, calcinates and fibrosis size ( p < 0.05). At weeks 7, 10, and 18, group 3 demonstrated significant ( p < 0.05) regression of symptoms for the parameters studied compared to groups 1 and 2. Conclusion: the presented treatment methods effectively alleviate CP symptoms and improve patients’ quality of life. The combination of ESWT and bovhyaluronidase azoximer shows significantly greater efficacy compared to ESWT monotherapy and the combination of ESWT with 3-As-therapy.

  • Long-term effect of extracorporeal shock wave therapy in combination with bovhyaluronidase azoximer in chronic prostatitis / chronic pelvic pain syndrome (clinical example)

    by M. V. Epifanova, А. А. Kostin, E. V. Slavkina, S. A. Artemenko, M. A. Vekilyan, А. А. Epifanov

    Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains a relevant medical issue in the modern world due to the lack of effective treatment options. The condition significantly impairs quality of life by negatively affecting sexual, reproductive, and psycho-emotional health. In recent years, increasing attention has been paid to the role of prostatic fibrosis in disrupting glandular function, contributing to urinary disorders, and reducing male fertility. Efforts are underway to identify optimal therapeutic strategies. This article presents a clinical case of a patient with pronounced prostatic fibrosis associated with CP/CPPS category IIIB. The treatment included a combination of extracorporeal shock wave therapy and the enzyme-based drug bovhyaluronidase azoximer. Following the treatment course, improvements were observed in clinical and laboratory parameters, as well as in the findings of instrumental diagnostic methods.

  • Recovery of erectile function in patients after radical prostatectomy using platelet rich plasma and extracorporeal shock wave therapy: a controlled study

    by M. V. Epifanova, S. A. Artemenko, А. А. Kostin, А. А. Epifanov, E. V. Slavkina

    Background. Prostate cancer (PCa) remains one of the leading oncological causes of morbidity in men. Despite advances in modern surgical techniques, including nerve-sparing radical prostatectomy (RP), erectile dysfunction (ED) remains a frequent and significant complication that substantially affects patients’ quality of life. Currently available rehabilitation methods have limitations in terms of effectiveness or accessibility. Aim. To evaluate the efficacy and safety of the combined use of autologous plasma enriched with platelet-rich plasma (PRP) and extracorporeal shockwave therapy (ESWT) in the restoration of erectile function in patients with erectile dysfunction following nerve-sparing radical prostatectomy. Materials and Methods. A prospective controlled study included 46 patients who had undergone unilateral or bilateral nerve-sparing robot-assisted RP. Group 1 received PRP injections combined with ESWT sessions. Group 2 (control) received tadalafil therapy. Assessments were conducted at baseline and on the 60th day of treatment. Validated scales were used: IIEF-5, SEP, EHS, IPSS, QOL, ICIQ-SF, GAQ, as well as penile vascular pharmacodopplerography (PDG), uroflowmetry (UFM), and total testosterone levels. Results. The combination therapy group (PRP + ESWT) demonstrated a significant improvement in erectile function indicators: IIEF-5 (p < 0.001), SEP (p < 0.001), EHS (p < 0.001), improved hemodynamics according to PDG (PSV and RI, p < 0.001), resolution of urinary incontinence symptoms per ICIQ-SF (p < 0.001), and improved urination according to UFM data (p < 0.001). No significant improvement in erectile function was recorded in the control group. No differences in safety profiles were observed between the groups. Conclusion. The combination of PRP and ESWT showed high clinical efficacy and safety in patients with postprostatectomy erectile dysfunction. This method warrants further investigation and may be recommended as an effective penile rehabilitation strategy following RP.

  • Combined physical and enzymatic therapy for chronic prostatitis and chronic pelvic pain syndrome.

    by M.V. Epifanova, Russia Moscow, A.A. Kostin, E.V. Slavkina, S.A. Artemenko, A.а. Epifanov

    Introduction. Chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) are the most prevalent urological disorders, affecting up to 14% of men and significantly reducing quality of life. The limited effectiveness of conventional treatment regimens increases interest in physiotherapeutic approaches, including extracorporeal shock wave therapy (ESWT), and in the use of enzymatic preparations. Objective. To evaluate the efficacy of ESWT, bovhyaluronidase azoximer (BA) as part of a treatment regimen in patients with Category II CP and Categories IIIA–IIIB CPPS. Materials and Methods. The randomized, open-label, placebo-uncontrolled study included 116 men aged 20–65 years (mean 45,5±9,5; disease duration 20,8±7,7 months). There were 3 study groups. Group 1 (n = 37) received ESWT + «3-As» therapy (antibiotic, NSAID, α-blocker); Group 2 (n = 38): ESWT monotherapy; Group 3 (n = 41): ESWT + BA (3000 IU). Efficacy was assessed at baseline and at weeks 7, 10, 18, 30, and 54 using the NIH-CPSI, IPSS, IIEF-5, and VAS scores, uroflowmetry, transrectal ultrasound with elastography and Doppler, and laboratory tests. Results. All patients completed treatment without adverse effects. Improvement at week 7 was most pronounced in Group 1 according to NIHCPSI, IPSS, VAS, and uroflowmetry (p < 0.05). By weeks 10–54, positive dynamics were observed in all groups, with the most stable and pronounced effect in Group 3, where ESWT combined with BA reduced the number and size of calcifications and fibrotic areas, increased normal elasticity regions, and improved prostatic blood flow. Intergroup analysis confirmed the superiority of Groups 1 and 3 over Group 2, with no significant differences between Groups 1 and 3. In patients with non-inflammatory CP/CPPS (IIIB), a significant improvement in erectile function (IIEF-5) was also recorded. Conclusions. ESWT, particularly when combined with BA, provides a significant reduction in CP/CPPS symptoms, improves uroflowmetry and ultrasound parameters of the prostate, and demonstrates superiority over standard therapy.

  • Open Access

    Assessment of kidney injury during immune-targeted therapy (pembrolizumab + axitinib) in patients with metastatic renal cell carcinoma and solitary kidney

    by K. S. Titov, M. V. Epifanova, A. A. Alimov, E. V. Shutov, O. Yu. Nesterova, S. S. Lebedev, G. M. Zapirov

    Aim. To assess the rate and type of kidney injury in the first 28 weeks of pembrolizumab and axitinib therapy after nephrectomy in patients with metastatic renal cell carcinoma and solitary kidney.Materials and methods. The retrospective study included 50 patients who previously underwent nephrectomy due to stage III–IV stage renal cell carcinoma. After nephrectomy prior to the start of antitumor therapy for cancer progression, 84 % of the patients were diagnosed with stage II and higher chronic kidney disease.Results. During antitumor drug treatment, acute kidney injury 14 and 28 weeks after the start of immune-targeted therapy was diagnosed in 4 % and 6 % of patients, respectively. Dynamics of the change in acute kidney injury in 28 weeks were not statistically significant (p = 0.983). Changes in serum creatinine, urea, and glomerular filtration rate were also insignificant. Statistically significant elevation of hemoglobin and hematocrit was observed during the 28 weeks of observation. Hemoglobin level increased from 128.1 g/L before the treatment to its maximal value of 141.7 g/L after the third injection of pembrolizumab (p 0.001).Conclusion. No significant kidney injury was observed during 28 weeks of observation in this single cohort study of patients with metastatic renal cell carcinoma after nephrectomy receiving pembrolizumab and axitinib.

  • A Randomized Controlled Clinical Trial on the Study of Autologous Plasma Enriched with Platelet Growth Factors and Extracorporeal Shock Wave Therapy in the Treatment of Peyronie’s Disease

    by M.V. Epifanova, Moscow 6 Miklukho-Maklaya St., А.а. Kostin, S.A. Artemenko, А.а. Epifanov, Moscow 127006 Fsbei He “Rosunimed” Of Moh Of Russia; 4 Dolgorukovskaya St.

    Background: The results of conservative methods of treating Peyronie’s disease (PD) do not exceed the placebo effect, and surgical treatment does not always lead to satisfactory outcomes. Aim: to evaluate the safety and effectiveness of using platelet rich plasma (PRP) and extracorporeal shock wave therapy (ESWT) in patients with PD. Materials and Methods: The study included 40 patients with PD, randomly assigned into two equal groups. Group 1 received ESWT (Dornier Medtech GmbH, Germany, D82234 Wessling, 62 Argelsrieder Feld, 7, Germany (FSZ 2011/09554) on the penis, targeting the fibrotic areas and calcifications twice weekly for 6 weeks. Group 2 underwent 2 visits per week for 6 weeks. Visit 1 involved PRP injections and ESWT on the penis, fibrotic areas, and calcifications. Visit 2 included only ESWT on the same areas. Outcomes were assessed on days 0 and 60 (median (IQR%)) using the Peyronie’s Disease Questionnaire (PDQ), Visual Analog Scale (VAS) during sexual intercourse and erection, penile curvature angle, plaque size, and calcifications based on penile ultrasound. Results: the treatment was well tolerated by all patients. No side effects were recorded. In group 2, one patient experienced disease progression, developing a «hourglass» deformity of the penis. Both groups showed significant reductions in pain and PD symptoms, as measured by VAS during erection (p = 0.001028, p < 0.001) and VAS during sexual intercourse (p = 0.01604, p < 0.001), as well as improvement in PDQ scores (p < 0.001, p < 0.001). The penile curvature angle also significantly decreased in both groups (p = 0.02364, p = 0.007346). While the size and number of calcifications decreased slightly (p > 0.05), the fibrotic plaque area showed significant regression in both groups (p = 0.001929, p = 0.003188). Post-treatment analysis showed a significant difference in plaque size reduction, VAS during erection, and during sexual intercourse in favor of patients who received APGF in combination with ESWT (p < 0.05). Conclusion: PRP and ESWT may represent a promising conservative strategy for treating PD. Combined therapy of APGF and ESWT is more effective in reducing pain and fibrotic plaque size in the penis compared to ESWT alone. Keywords: Peyronie’s disease, platelet rich plasma, extracorporeal shock wave therapy, growth factors, regenerative medicine, erectile dysfunction.

  • Surgical treatment of local renal cell carcinoma recurrence. Surgical aspects and oncological results

    by M. Ya. Gaas, A. D. Kaprin, A. A. Kostin, M. V. Epifanova, N. V. Vorobyev, R. O. Inozemtsev, A. S. Kalpinsky, S. A. Guskova, N. A. Sorochinskiy

    Introduction. Treatment of local RCC recurrence is a serious surgical and therapeutic problem. There is no single standard strategy for the treatment of locally recurrent RCC. Objective: to evaluate the short- and long-term results of surgical treatment of patients with local RCC recurrence. Material and methods. Among all participants (n=53), 48 patients had isolated local RCC recurrence (group 1), and 5 had synchronous metastases (group 2). All patients had one or more local foci of RCC and underwent radical removal of all foci from may 2007 to January 2024. In distant metastases, metastasectomy was performed. Results. Laparotomy was the preferred access (75.4 %). The average duration of surgery was 167.5 minutes in group 1 and 300 minutes in group 2 (p=0.008). In the early postoperative period, 10 people had postoperative complications. The median follow-up period was 68.17 ± 9.17 (95 % CI 17.00; 112.50) months in group 1 and 79.60 ± 12.17 (95 % CI 47.50; 123.50) in group 2 (p=0.493). The median RFS in group 1 was 139.86 ± 11.02 (95 % CI 119.00; 154.50) months and 100.67 ± 10.22 (95 % CI 91.00; 121.00) months in group 2 (p=0.375), while the local RFS was 174.80 ± 12.22 (95 % ci 139.00; 194.50) and 126.00 ± 11.40 (95 % CI 109.20; 142.40) months in groups 1 and 2, respectively (p=0.352). The median PFS was 193.00 ± 11.22 (95 % ci 172.02; 209.50) months in group 1 and 121.13 ± 11.14 (95 % CI 111.00; 146.43) months in group 2 (p=0.266). The median OS was 149.70 ± 11.20 (95 % CI 123.12; 161.43) months in the group 1 and 56.50 ± 11.20 (95 % CI 33.20; 78.42) months in the group 2 (p=0.169). The 5-year CSS was 85.7 % in group 1 and 40 % in group 2 (p=0.096). The 10-year CSS rate was 81 % and 4 % in groups 1 and 2, respectively (p=0.109). Conclusion. Surgical intervention is effective treatment for local recurrence, providing good oncological outcomes; however, size and proximity to neighboring organs can significantly impact the risk of perioperative complications.


  • Open Access

    Is platelet-rich plasma and extracorporeal shock wave therapy a new frontier in treating patients with erectile dysfunction?

    by M. V. Epifanova, А. А. Kostin, S. A. Artemenko, А. А. Epifanov

    Background. Existing methods for treating erectile dysfunction (ED) do not always provide the necessary therapeutic effect and/or may not be recommended for certain patients. Aim. Evaluate the effectiveness of correcting erectile dysfunction using platelet-rich plasma (PRP) and extracorporeal shock wave therapy (ESWT). Material and methods . 100 men were randomly assigned to 3 groups. Group 1 (n=20) received ESWT treatment on the penis twice a week for 6 weeks. Group 2 (n=40) and Group 3 (n=40) had two visits per week for 6 weeks, involving both ESWT and PRP injections into the penis. In Group 2, PRP activation was performed using ESWT, while in Group 3, it was done using a 10% solution of CaCl2. Patients were evaluated at 0 and 60 days of the study, assessing IIEF-5, SEP, EHS, GAQ, blood testosterone levels, and penile Doppler ultrasound with PGE1. Results. In group 1 IIEF-5 improved from 14.5 (10.5-17) to 19.5 (15.5-21) (рConclusion. All treatment methods were well-tolerated by all patients. The study results indicate a positive trend in improving erectile function and increasing total testosterone levels in the blood. When comparing groups, combination therapy significantly improves erectile function according to SEP, EHS, and penile Doppler ultrasound assessments. ESWT can be suggested as an activator for PRP.

  • Open Access

    Technologies of regenerative medicine as a method of treatment of male infertility: literature review

    by M. V. Epifanova, А. А. Kostin, А. А. Epifanov, K. A. Kirillova

    The problem of infertility has recently become quite widespread all over the world, having a negative impact on couples themselves and society as a whole. The male factor of infertility accounts for about 50% of cases, in this regard, a large number of studies conducted are aimed at finding new methods of treating this disease. However, the accepted modern methods of treatment, including assisted reproductive technologies, are currently not effective enough. Recently, much attention has been devoted to the use of regenerative medicine technologies in the treatment of diseases of the reproductive system of men and women due to its significant potential. This review presents existing experimental and clinical studies that studied the effect, safety and efficacy of stem cells of various kinds of origin, induced pluripotent stem cells, exosomes, spermatogonial stem cells, platelet rich plasma in the treatment of various types of male infertility.